Cervical Cancer clinical trials in Delaware

5 actively recruiting cervical cancer trials at 4 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07061977

Sites in Delaware:

Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Beebe Health Campus — Rehoboth Beach, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca

NCT ID: NCT07431281

Sites in Delaware:

Research Site — Newark, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …

Sponsor: NRG Oncology

NCT ID: NCT07441681

Sites in Delaware:

Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware
Christiana Care Health System-Wilmington Hospital — Wilmington, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06064097

Sites in Delaware:

Alfred I duPont Hospital for Children — Wilmington, Delaware

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc

NCT ID: NCT04585750

Sites in Delaware:

Medical Oncology Hematology Consultants — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01